Physician profile
Pranab Das
NPI 1528260460
$10,561.49
in general payments reported to CMS, 2019-2025
23 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,380 · 2020: $2,221 · 2021: $1,277 · 2022: $1,128 · 2023: $1,120 · 2024: $1,326 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,193 · Travel and Lodging: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,192.63 |
| Travel and Lodging | $363.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,390.32 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Symplicity G3 |
| Medtronic Vascular, INC. | $2,139.47 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $948.03 | 2019-2020 | |
| Abbott Laboratories | $828.52 | 2019-2024 | Navitor, Accent, Quadra Assura |
| Edwards Lifesciences Corporation | $772.78 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $488.19 | 2020-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $396.71 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $354.05 | 2019-2024 | Farxiga |
| Boston Scientific Corporation | $300.31 | 2023-2025 | Avvigo Guidance System, Eluvia |
| Cardiovascular Systems INC. | $289.14 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $151.10 | 2019-2022 | |
| Cvrx, INC. | $124.60 | 2021-2023 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $119.96 | 2024-2025 | Winrevair |
| Avinger INC. | $72.20 | 2022-2023 | Pantheris |
| Abiomed | $31.50 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $30.76 | 2022 | |
| Bard Peripheral Vascular, INC. | $26.49 | 2019-2020 | |
| United Therapeutics Corporation | $23.90 | 2021 | |
| Pfizer INC. | $18.63 | 2022 | |
| Atricure, INC. | $15.20 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $15.14 | 2025 | Rhythm Express |
| Biotronik INC. | $12.74 | 2019 | |
| Biosense Webster, INC. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranab Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.